tbuckley/cabot-search huggingface dataset:
Medical Spanish
Authors: Anna K. Brady
Journal: Annals of Internal Medicine (2010)

On Being a Doctor19 January 2010Medical SpanishAnna K. Brady, BS, BAAnna K. Brady, BS, BAFrom Cleveland Clinic Lerner College of Medicine, Cleveland, OH 44195.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-152-2-201001190-00014 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In another life, I might have been a linguist. Instead, I double as a translator for my coworkers at the hospital: other medical students, residents, nurses, whomever. My accent is Castilian and my Puerto Rican slang nonexistent, but otherwise I speak fluent Spanish.Translation, however, is a tricky business. One often confronts the conflict between translating words and translating ideas. In the hospital setting, we emphasize the translation of words. Even when no language barrier exists, the ideas may not get through."Do you know medical Spanish?" my attending asks on a Friday morning, as we are gathered around the ... Author, Article, and Disclosure InformationAffiliations: From Cleveland Clinic Lerner College of Medicine, Cleveland, OH 44195.Corresponding Author: Anna K. Brady, BS, BA, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, 9500 Euclid Avenue, NA 21, Cleveland, OH 44195; e-mail, [email protected]org. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 19 January 2010Volume 152, Issue 2Page: 127-128KeywordsAbscessesBiopsyColonoscopyMouthPreexposure prophylaxisRectumShouldersSurgeonsSurgeryTaste ePublished: 19 January 2010 Issue Published: 19 January 2010 Copyright & PermissionsCopyright © 2010 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Peritoneoscopy
Authors: Sumner C. Kraft
Journal: JAMA (1966)

Peritoneoscopy is a valuable diagnostic procedure which for many years has been used extensively in Europe and South America. It has also been discussed in varying detail in several English language texts of gastroenterology, gastrointestinal endoscopy, and diseases of the liver. Nevertheless, despite reports of successful experiences by numerous American endoscopists, peritoneoscopy has not enjoyed widespread usage in this country and seems to have been underrated. If our difficulty in accepting this procedure has been due partly to the lack of an illustrated text exclusively devoted to peritoneoscopy, these two volumes would seem to fill a real need. They have been capably translated from Hungarian. In the first volume Dr. Wittman initially presents background information and details pertaining to instrumentation and technique. The step-by-step discussions of procedures for safely producing pneumoperitoneum, introducing the peritoneoscope, and systematically inspecting the abdominal cavity, are especially well done. The indications, contraindications, dangers, and complications
Symptoms in Pediatric Asthmatics and Air Pollution: Differences in Effects by Symptom Severity, Anti-Inflammatory Medication Use and Particulate Averaging Time
Authors: Ralph J. Delfino, Robert S. Zeiger, James M. Seltzer, Donald H. Street
Journal: Environmental Health Perspectives (1998)

Experimental research in humans and animals points to the importance of adverse respiratory effects from short-term particle exposures and to the importance of proinflammatory effects of air pollutants, particularly O(subscript)3. However, particle averaging time has not been subjected to direct scientific evaluation, and there is a lack of epidemiological research examining both this issue and whether modification of air pollutant effects occurs with differences in asthma severity and anti-inflammatory medication use. The present study examined the relationship of adverse asthma symptoms (bothersome or interfered with daily activities or sleep) to O(3) and particles (less than or equal to)10 micrometer (PM10) in a Southern California community in the air inversion zone (1200-2100 ft) with high O(3) and low PM (R = 0.3). A panel of 25 asthmatics 9-17 years of age were followed daily, August through October 1995 (n = 1,759 person-days excluding one subject without symptoms). Exposures included stationary outdoor hourly PM10 (highest 24-hr mean, 54 microgram/m(3), versus median of 1-hr maximums, 56 microgram/m(3) and O(3) (mean of 1-hr maximums, 90 ppb, 5 days (greater than or equal to)120 ppb). Longitudinal regression analyses utilized the generalized estimating equations (GEE) model controlling for autocorrelation, day of week, outdoor fungi, and weather. Asthma symptoms were significantly associated with both outdoor O(3) and PM(10) in single pollutant- and co-regressions, with 1-hr and 8-hr maximum PM(10) having larger effects than the 24-hr mean. Subgroup analyses showed effects of current day PM(10) maximums were strongest in 10 more frequently symptomatic (MS) children: the odds ratios (ORs) for adverse symptoms from 90th percentile increases were 2.24 [95% confidence interval (CI), 1.46-3.46] for 1-hr PM10 (47 microgram/m(3); 1.82 (CI, 1.18-2.81) for 8-hr PM10 (36 microgram/m(3); and 1.50 (CI, 0.80-2.80) for 24-hr PM10 (25 microgram/m(3). Subgroup analyses also showed the effect of current day O(subscript)3 was strongest in 14 less frequently symptomatic (LS) children: the ORs were 2.15 (CI, 1.04-4.44) for 1-hr O(3) (58 ppb) and 1.92 (CI, 0.97-3.80) for 8-hr O(3) (46 ppb). Effects of 24-hr PM10 were seen in both groups, particularly with 5-day moving averages (ORs were 1.95 for MS and 4. 03 for LS; p(less than or equal to)0.05). The largest effects were in 7 LS children not on anti-inflammatory medications [5-day, 8-hr PM10, 9.66 (CI, 2.80-33.21); current day, 1-hr O(3), 4.14 (CI, 1.71-11.85)]. Results suggest that examination of short-term particle excursions, medication use, and symptom severity in longitudinal studies of asthma yields sensitive measures of adverse respiratory effects of air pollution.
BARIS: A phase I trial to evaluate the safety and tolerability of combined BIBF 1120 and RAD001 in solid tumors and to determine the maximum tolerated dose (MTD) of the combination.
Authors: Matthias Scheffler, Masyar Gardizi, Marc Christiaan Allardt Bos, Lucia Nogova, Sebastian Michels, Thorsten Persigehl, Martin L. Sos, Felix Dietlein, Thomas Zander, Juergen Wolf
Journal: Journal of Clinical Oncology (2014)

TPS2645^ Background: Simultaneous inhibition of several signalling pathways involved in angiogenesis as well as in tumor cell growth regulation by kinase inhibitor combination therapy may increase therapeutic efficacy. Here we evaluate the combination of the mTOR-inhibitor RAD001 (everolimus) and the triple kinase (FGFR, VEGFR, PDGFR) inhibitor BIBF 1120 in a phase I trial in advanced solid tumors. In addition we use DCE-MRI for early identification of patients with benefit from BIBF 1120 Methods: Patients in arm A receive 5 mg of RAD001 and 2 x 150 mg BIBF 1120, in arm B 10 mg RAD001 and 2 x 150 mg BIBF 1120 will be administered, whereas in arm C, 10 mg of RAD001 and 2 x 200 mg BIBF 1120 will be given. Eligible are all patients with relapsed or refractory advanced/metastatic solid tumors and an ECOG performance state of 0-1 for whom no further standard therapies are available. All patients will start with a 2-week run-in phase of 2 x 200 mg BIBF 1120. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) scans will be performed at baseline staging, on day 3 and day 14. On day 14, there will also be 12 hours-pharmacokinetic (PK) assessment. Combination therapy starts on day 15. On day 29, a DCE-MRI scan and 12-hours PK will be performed. Restaging is performed on day 57. Patients who experience clinical benefit (i. e., response or stable disease) on day 57 with adequate tolerability of the combination will further receive the medication, as long as the benefit lasts. Results: 15 patients have been enrolled so far in arm A and B, and one patient started in arm C. Of the enrolled patients, the majority (9 patients) had non-small cell lung cancer (NSCLC) as the underlying tumor. Two patients turned out to be screening failures in arm B. The trial procedures proved to be feasible. Discussion: So far, the combination of BIBF 1120 and RAD001 has reached its predefined third dosage step. We expect the termination of the trial by summer 2014. In case of efficacy in a molecular defined subset of patients, an expansion phase (phase II) is planned. Clinical trial information: NCT01349296.
The ORCHESTRA trial: A phase III trial of adding tumor debulking to systemic therapy versus systemic therapy alone in (mCRC) multi-organ metastatic colorectal cancer.
Authors: Elske C. Gootjes, Tineke E Buffart, M.P. Tol, J Burger, Dirk J. Grunhagen, Eric P van der Stok, Martijn R. Meijerink, Albert J. Ten Tije, Esther Van Meerten, Peter M van de Ven, Joost Nuyttens, Cornelis J Haasbeek, Cornelis Verhoef, Henk M.W. Verheul
Journal: Journal of Clinical Oncology (2015)

TPS3631 Background: In the current multidisciplinary approach of mCRC, local treatment of oligometastases is common practice. Results of large case series of selected patients treated with complete surgical resection of metastatic lesions suggest that this approach substantially improves survival rates to around 30-60%. Other techniques such as radiofrequency or microwave ablation (RFA, MWA), transarterial chemoembolization (TACE) or stereotactic ablative radiotherapy (SABR) can also be applied in local treatment. Curative treatment options are generally not available for patients with extensive hepatic and/or extrahepatic mCRC. These patients primarily receive palliative systemic treatment consisting of combination chemotherapy as well as targeted agents. So far, reports on the benefit of local treatment for metastases in multi-organ mCRC have major limitations, including being small, non-randomized, single-center and retrospective. The benefit from local treatment of metastases for these patients should be established to allow for interruption of the standard systemic therapy and exposure to possible adverse events from local treatment. Methods: The ‘ORCHESTRA’ trial is a randomized multicenter clinical trial for patients with multi-organ mCRC, comparing the combination of chemotherapy and maximal tumor debulking versuschemotherapy alone (NCT01792934). We will examine the interplay of both efficacy and toxicity for the combination of systemic chemotherapy and locoregional therapy. Our study design incorporates systemic as well as local therapy in the experimental arm and combines local treatment modalities to pursue maximal tumor debulking. We aim to improve overall survival of patients with multi-organ mCRC by maximal tumor debulking after induction chemotherapy with at least six months. A total of 478 patients will be included to meet the primary endpoint (power 80%, type I error rate 5%). We define local treatments feasible when they can be performed within a 3-month time period to prevent extensive delay of systemic therapy. Currently, 34 patients are included in 19 participating Dutch hospitals. Clinical trial information: NCT01792934.
Digest
Authors: E. El-Omar, S. Vermeire, A. Gerbes
Journal: Gut (2010)

H pylori and the acid pumpH pylori infection causes gastritis and transient hypochlorhydria, which may progress after decades to a gastric cancer phenotype.CagA positive strains increase cancer risk but their effect on acid secretion is poorly understood.Acid secretion is mediated by the catalytic a subunit of parietal cell H, K-ATPase (HKa).Saha et al sought to identify bacterial genes involved in HKa repression and to assess their impact on acid secretion.AGS cells transfected with an HKa promoter construct or human gastric body biopsies were infected with wild-type (wt) or isogenic mutant (IM) strains.AGS cell HKa promoter activity, and biopsy HKa mRNA, protein and H+ secretory activity were measured.The authors showed that the H pylori cag PAI genes cagL, cagM and cagE are implicated in repression of HKa transcription following acute infection, and that this repression is reflected in markedly diminished HKa translation and ensuing H, K-ATPase activity in H pylori-infected gastric biopsies (see figure 1).The study demonstrates a novel model that allows controlled exposure of human gastric mucosa to different H pylori strains and refined pharmacological interventions to dissect the affected cellular signalling pathways.See page 874.
Hepatology Highlights
Authors: Robert E. Schwartz, Jennifer Batisti, Robert S. Brown, Zaid Tafesh, Nicole Shen, Nicholas Russo, Russell Rosenblatt, Emily Schonfeld, Shirley Cohen‐Mekelburg, Vikas Gupta
Journal: Hepatology (2017)

Schwartz, Robert E.; Batisti, Jennifer; Brown, Robert S. Jr.; Tafesh, Zaid; Shen, Nicole; Russo, Nicholas; Rosenblatt, Russell; Schonfeld, Emily; Cohen‐Mekelburg, Shirley; Gupta, Vikas Author Information
Progress in Roentgenology of the Liver and Biliary Tract
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
II. ON SUTURE OF NERVES, AND ALTERNATIVE METHODS OF TREATMENT BY TRANSPLANTATION OF TENDON
Authors: R. Jones
Journal: BMJ (1916)

TuE Banso 67gMy colleague, Mr. Woodman, made a tlhorouglh examina- tion of the nose and accessory sinuses.Transillumination glhowed nothiing patlhological, and there was no evidence of any intranasal disease.Tlle plharyngeal ends of the Eustaclhian tubes were enlarged and oedematous.A radiograpli slhowed nothiing definite, but the orbital roof on the righlt side was not as well defined as on the left.Tlhere was a faint lhaze of album-iin in the urine.The Wassermann test was negative.The puilse-rate was normnal, but fell onice after adm-sission to 64.Tlle tem- perature on admission was 99.40, and afterwards fluctuated between 970 and normal.He was admitted witll the diagnosis of orbital growvtl, probably sarcomna growing from the region of the splhenoid.There vias never any sickness nor complaint of any hieadaclhe.He died on Novermber 5il witlh typical respi- ratory failure.For about forty-eiglhthours beforedeatl hle was ratlher peculiar mentally, and got up during the nighlt and wandered about thle ward.He never displayed any general symptoms to suggest initracranial trouble.Post-ntmoric Examtinattion..I was present at the post-mnortemi examination, wbhicl was made by tlle pathologist, Dr. L. Walker.No abnor- mality was found apart fromn tlle central nervous svstem aind orbit.Tlle meningeal coverings over the orbital surface of the riglht frontal lobe of the brain were almost a qiiai-ter of an inchl tlhick.Tlhe memnbranes were vascular and adherent botlh to the brain and roof of the orbit.The bone here, as well as in tlle neiglhbourhood of the nasal sinuses, was eroded, soft, and friable, being largely re- placed by fibrous-looking tissuie.Thle orbital roof was considerably displaced downwards.Tissue of fibrous
Manuscripts Approved for JNCI, December 1, 1968, to January 1, 1969
Journal: JNCI Journal of the National Cancer Institute (1969)

Manuscripts Approved for JNCI, December 1, 1968, to January 1, 1969 Get access JNCI: Journal of the National Cancer Institute, Volume 42, Issue 2, February 1969, Pages 345–346, https://doi.org/10.1093/jnci/42.2.345 Published: 01 February 1969
GASTBOENTEROSTOMY.
Authors: WILLIAM H. WATHEN
Journal: JAMA (1905)

It is conceded by the best authorities in both surgery and internal medicine that efficient drainage by some of the various surgical operations devised is the correct and only successful treatment for many diseased conditions of the stomach and duodenum, usually diagnosed as chronic indigestion; and for hemorrhage in acute ulcer of the stomach that resists medical treatment and is endangering the life of the patient; or for continued and profuse hemorrhage in chronic gastric ulcer; and for perigastric adhesions or stomach infiltration and contraction, that disturb the physics of digestion. There is not a consensus of opinion by our best abdominal surgeons, however, as to the method of drainage that accomplishes the best results in all cases. Hence, let us consider the facts bearing on the operations that have been performed, and decide which one of the several is the most logical, and has given and must give the best immediate and ultimate results.
Diuretics
Authors: Laurence E. Earley
Journal: New England Journal of Medicine (1967)

DIURETIC agents afford an empirical approach to the management of patients with cardiac-failure, the nephrotic syndrome or liver disease, when these disorders lead to the retention of salt and water by the kidney, with the resultant accumulation of edema or ascites or both. It is beyond the scope of this paper to discuss the possible pathways whereby these diseases result in pathologic retention of salt and water by the kidney, but it should be emphasized that the pooling of extracellular fluid in the peritoneal cavity or the generalized interstitial spaces of the body may be a direct consequence of the . . .
Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR
Authors: Hongbing Zhang, Gregor Cicchetti, Hiroaki Onda, Henry B. Koon, Kirsten Asrican, Natalia Bajraszewski, Francisca Vazquez, Christopher L. Carpenter, David J. Kwiatkowski
Journal: Journal of Clinical Investigation (2003)

Tuberous sclerosis (TSC) is a familial tumor syndrome due to mutations in TSC1 or TSC2, in which progression to malignancy is rare. Primary Tsc2–/– murine embryo fibroblast cultures display early senescence with overexpression of p21CIP1/WAF1 that is rescued by loss of TP53. Tsc2–/–TP53–/– cells, as well as tumors from Tsc2+/– mice, display an mTOR-activation signature with constitutive activation of S6K, which is reverted by treatment with rapamycin. Rapamycin also reverts a growth advantage of Tsc2–/–TP53–/– cells. Tsc1/Tsc2 does not bind directly to mTOR, however, nor does it directly influence mTOR kinase activity or cellular phosphatase activity. There is a marked reduction in Akt activation in Tsc2–/–TP53–/– and Tsc1–/– cells in response to serum and PDGF, along with a reduction in cell ruffling. PDGFRα and PDGFRβ expression is markedly reduced in both the cell lines and Tsc mouse renal cystadenomas, and ectopic expression of PDGFRβ in Tsc2-null cells restores Akt phosphorylation in response to serum, PDGF, EGF, and insulin. This activation of mTOR along with downregulation of PDGFR PI3K-Akt signaling in cells lacking Tsc1 or Tsc2 may explain why these genes are rarely involved in human cancer. This is in contrast to PTEN, which is a negative upstream regulator of this pathway.
Erratum to: Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay
Authors: Wendy E. Heywood, Daniela Galimberti, Emily Bliss, Ernestas Sirka, Ross W. Paterson, Nadia K. Magdalinou, Miryam Carecchio, Emma Reid, Amanda Heslegrave, Chiara Fenoglio, Elio Scarpini, Jonathan M. Schott, Nick C. Fox, John Hardy, Kailash P. Bhatia, Simon Heales, Neil J. Sebire, Henrik Zetterberg, Kevin Mills
Journal: Molecular Neurodegeneration (2016)
From the Surgeon General, US Public Health Service
Authors: A. C. Novello
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical News
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CHICAGO SOCIETY OF OPHTHALMOLOGY AND OTOLOGY.
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal